Vildagliptin Drug Profile

What is Vildagliptin?

Vildagliptin is an oral antidiabetic medication belonging to a class of drugs called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). It is primarily used to treat type 2 diabetes mellitus by helping to control blood sugar levels. This medication works by enhancing the body’s natural ability to regulate glucose through the incretin hormone system.

Uses

• Type 2 diabetes mellitus: Primary indication for managing blood glucose levels in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic medications
• Combination therapy with metformin: Often prescribed alongside metformin when metformin alone is insufficient to achieve target blood sugar levels
• Combination with sulfonylureas: Used with sulfonylurea medications when these drugs alone do not provide adequate glycemic control
• Triple therapy regimens: May be combined with metformin and sulfonylureas or other antidiabetic agents for comprehensive diabetes management
• Alternative to insulin therapy: Sometimes used as an alternative treatment option for patients who cannot tolerate insulin or prefer oral medications

How it works

Vildagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which normally breaks down incretin hormones like GLP-1 and GIP. By blocking this enzyme, vildagliptin increases the levels of these beneficial hormones, which stimulate insulin release when blood glucose is elevated and suppress glucagon secretion when it’s not needed. This glucose-dependent mechanism helps lower blood sugar levels while reducing the risk of hypoglycemia.

Side effects

Common side effects:

• Headache
• Dizziness
• Nausea
• Upper respiratory tract infections
• Constipation
• Peripheral edema (swelling in hands or feet)
• Fatigue
• Joint pain

Serious side effects to watch for:

Submit Your Paper

• Severe hypoglycemia (especially when combined with sulfonylureas or insulin)
• Liver function abnormalities or hepatitis
• Severe joint pain that may be disabling
• Signs of pancreatitis (severe abdominal pain, nausea, vomiting)
• Allergic reactions including skin rash or angioedema

Warnings and precautions

• Liver function monitoring: Regular liver function tests are recommended as vildagliptin can cause elevated liver enzymes and, rarely, liver injury
• Kidney impairment: Dosage adjustments are necessary for patients with moderate to severe kidney disease, and the medication should be used with caution
• Pregnancy and breastfeeding: Limited safety data available; use only if potential benefits outweigh risks and consult healthcare provider
• Heart failure: Use with caution in patients with heart failure as DPP-4 inhibitors may increase the risk of hospitalization for heart failure in some patients
• Pancreatitis history: Patients with a history of pancreatitis should be monitored carefully and discontinue use if pancreatitis is suspected

Interactions

• ACE inhibitors: May increase risk of angioedema when used together
• Insulin and sulfonylureas: Increased risk of hypoglycemia; dosage adjustments of these medications may be necessary
• Thiazide diuretics: May reduce the glucose-lowering effect of vildagliptin
• Corticosteroids: Can increase blood glucose levels, potentially reducing vildagliptin’s effectiveness
• Beta-blockers: May mask symptoms of hypoglycemia and affect glucose metabolism
• Alcohol: Can increase risk of hypoglycemia and should be consumed with caution
• St. John’s Wort: May affect drug metabolism and glucose control
• Warfarin: Monitor INR closely as diabetes medications can affect anticoagulation

Check interactions with the GMJ Interaction Checker

Dosage

The typical adult dosage for vildagliptin is 50 mg twice daily, taken with or without food. When used as monotherapy or in combination with metformin, the standard dose is 50 mg in the morning and 50 mg in the evening. For patients with moderate to severe kidney impairment, the dose should be reduced to 50 mg once daily. Dosage adjustments may also be necessary when combining with other antidiabetic medications to minimize the risk of hypoglycemia. Always follow your healthcare provider’s specific dosing instructions, as individual dosage requirements may vary based on kidney function, other medications, and blood glucose control.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).